J P D

Malaria transmission and disease burden in Assam: challenges and opportunities

V. Dev • V. P. Sharma • D. Hojai

Received: 22 October 2009 / Accepted: 9 November 2009 ©2009 Indian Society for Parasitology

Abstract Malaria is major public health illness in Assam and 30-40% of the population is estimated to be at highrisk. Despite decades of attempted control interventions, malaria transmission is perennial and persistent in most parts of the state mostly transmitted by Anopheles minimus. Malaria outbreaks are returning associated with high rise in Plasmodium falciparum and attributable death cases. Therapeutic efficacy investigations for treatment of malaria revealed that chloroquine resistance was widespread for which artemisinin-based combination therapy (ACT) is being instituted in the control program. For data based on the preceding years, we briefly reviewed the available information on transmission dynamics, vector biology and control, drug policy, and discuss the challenges and opportunities for strengthening interventions for malaria control to help design situation specific strategies to check impending disease outbreaks with special reference to Assam. Under increased assistance from external agencies, we strongly advocate scaling up interventions based on mass distribution of long-lasting insecticidal nets (LLINs) for prevention and ACTs for treatment of drug-resistant malaria, and developing strong health delivery system in high-risk areas for meeting the complex emergencies and achieving transmission reduction.

V. Dev¹[⊠] • V. P. Sharma² • D. Hojai³ ¹National Institute of Malaria Research (ICMR), Chachal, Guwahati - 781022, Assam, India ²Centre for Rural Development and Technology, Indian Institute of Technology, Hauz Khas, New Delhi - 110016, India ³State Health Directorate, Government of Assam, Hengrabari, Guwahati - 781036, Assam, India e-mail: mrcassam@hotmail.com Keywords Malaria control, *P. falciparum*, Morbidity and mortality, *Anopheles minimus*, Drug-resistance, Assam, Northeast India

Introduction

Northeastern states of India (22°.4'-29°.31' N lat; 89°.48'-97°.25' E long) are malaria endemic and contribute 10-12% of cases and >20% of deaths annually (Dev et al. 2003). Assam is the major constituent state that alone accounts for 70% of the total population (30.56 million) contributing >50% of reported cases in the northeast. The region is endowed with rich biodiversity associated with heavy rainfall (2-3 meters) and malaria receptivity is high with estimated 30-40% population at high-risk (Dev et al. 2006a). Nearly 40% of the land area is under forest cover and large tracts are flood prone rendering them inaccessible. Malaria is major public health illness in the state reporting focal disease outbreaks characterized by high rise in cases and deaths attributable to Plasmodium falciparum (Prakash et al. 2000). The transmission of the causative parasites is perennial with peaks during April-September corresponding with months of rainfall. Given the terrain and ethnic heterogeneity, disease is unevenly distributed across the state with varying risk factors and intensities of malaria transmission maintained by Anopheles minimus in foothill villages and by A. baimaii (formerly species D of A. dirus species complex) in forested/forest fringe areas (Dev et al. 2004). With the countrywide launching of National Malaria Eradication Program in 1958, there was spectacular reduction in cases but unlike other parts of India, majority malaria units in Assam remained under attack phase for DDT residual spraying (Sharma 1996). Since both vector species are still susceptible to DDT, it remains the insecticide of choice for vector control. However, despite decades of attempted control, malaria is a major impediment for socioeconomic development of the region. We report the retrospective analysis of malaria scenario, and briefly review the available information on transmission dynamics, vector biology and control, drug policy, and discuss the challenges and opportunities for strengthening interventions for malaria control with special reference to Assam.

Malaria transmission and attributable morbidity and mortality

There are 156 block level Primary Health Centres (PHCs) that have diagnostic facilities and serve as reporting units for malaria in Assam. The data retrieved from all sources for the past 10 years (1998-2008) are presented in Table 1 It may be noted that annual blood examination rate (ABER) for each year remained <10%, a primary cause of underreporting due to poor disease surveillance. In these bloodsmears, malaria parasite rate varied from 3.12-4.59%, majority of which were P. falciparum cases (58-69%). The annual parasite incidence (API) ranged from 2.02-4.91 per thousand population/year. Given the DDT spray coverage (>70% of target population) against malaria transmitting mosquito species, disease surveillance and treatment of cases, malaria transmission remained high, and as a result deaths due to malaria were common. All deaths were due to P. falciparum as confirmed by microscopic examination of blood-smear and/or rapid diagnostic test kit. Data analysis for 2007-2009 revealed that deaths were reported from all age groups of both sexes but were significantly higher in males (p < 0.05), and majority occurred in age group >15 years (Table 2).

Vector biology and control

Anopheles minimus is unequivocally proven as the major malaria vector in foothill areas of Assam valley (Dev et al. 2004). It is most abundant and widely prevalent for most part of the year. It is a typical indoor-resting species and have strong predilection for human host for blood feeding with peak biting activity during 01:00–04:00 hours. It breeds in slow-flowing seepage water streams which are innumerable in all foothill districts maintaining perennial transmission. *A. baimaii* is the only other vector species but of seasonal importance with distribution restricted to deep forest fringe areas (Prakash et al. 2001). *A. fluviatilis* mostly prevalent during winter months (January–March) has now been characterized merely a morphological and seasonal form of *A. minimus* (O.P. Singh, personal communication).

These vector species are susceptible to DDT residual spraying but are less amenable to control due to species specific behavioral characteristics. Systematic monitoring of vector density revealed that A. minimus avoided resting indoors for 10-12 weeks postspraying permitting extradomiciliary transmission related to forest related livelihood (unpublished observ.). Situational analyzes of the high-risk districts revealed that interventions based on DDT spray operations were poorly applied, and for some years second round of spray was not done (Prasad 2009). Community refusal rates for indoor spraying were >50% amounting to low coverage so much so that there was no correlation between DDT used and malaria transmission intensities for the period observed (Table 1). A. baimaii is a jungle pool breeder and rests outdoors avoiding direct contact with sprayed surfaces rendering control interventions ineffective (Prakash et al. 1997). The relative abundance of A. fluviatilis during winter months may be due to lack of DDT spraying of which two rounds are usually undertaken during March-August corresponding to peak transmission period.

Given the scenario, we strongly advocate alternative interventions that are community-based and environmental friendly such as insecticide-treated nets (ITNs)/ longlasting insecticidal nets (LLINs) as personal protection against these vector species that are highly anthropophilic and difficult to control. ITNs/LLINs are widely accepted by the communities and proven to be effective in the control of malaria transmitting mosquitoes in Assam (Dev 2009). What is important is targeting interventions in right place and right time to check transmission in the face of rapid urbanization, population migration and changing ecology for effective mosquito vector control.

Malaria outbreaks and containment practices

Most districts in Assam share an international or interstate border (Fig. 1). This population is estimated between 30 and 40% and categorized high-risk for malaria and prone to focal disease outbreaks. Retrospective analysis of data

	*
1	08)
	2-7
	3661
	<u>a</u>
;	Indi
	ast
,	The
	, no
	ssam,
	In A
	SUC
	ventic
	erve
	inté
,	itrol
	con
	ctor
,	lve
	anc
	ties
	ensi
	1 int
	sion
	mis
	transi
	ITIA
ļ	Iala
	able
	la

Positive for factorum factorum for confirmed for formina (76)Inscidence (No. (No. for formina (76)Inscidence (No. (No. (No. (76))Instanton (No. (76))Cuantity used in kg (No. (76))caseCuantity used in kg (76,0))casecase (76) 53.383.44.91[458872]Not done87790400111 (70) 3.1514492590(61.89)95173383394534.3123 (2.33) 61.973.4815645797Not done9177660122 (2.40) 61.973.4814498256Not done9177660122 (2.40) 71.212.0214408712583809482353729295673 (2.40) 71.212.021444089707162580288537844953 (2.21) 41.400777.459707162580288537844953 (2.21) 71.212.02118.42156Not done7975530111 (2.22) 66.953.3412964867Not done7975530113 (2.21) 71.212.02118.42156Not done7975530113 (2.22) 66.953.3412964867Not done7975530	Year Population No. and (%) of blood-sme in millions	No. and (%	No. and (%) of blood-smears	smears	% of positive blood-	Annual parasite		DDT data			No. of death
falcipurumcases/1,000Ist sprayIst spray2nd sprayIst2nd 57.86 3.61 1458872 Not done 877904 0 57.86 3.61 1456872 Not done 877904 0 63.38 4.91 15345286 6031876 1081477 363830 1 61.37 3.15 14592590 6967822 937238 339453 1 61.37 3.15 14592590 6967822 937238 339453 1 61.97 3.48 15645797 Not done 917766 01 61.97 3.21 1408712 5838094 823537 292956 0 61.30 3.21 1408712 5838094 823537 292956 01 62.30 3.214 1144089 77765 802885 378449 01 63.53 2.744 1144089 77765 802885 378449 01 63.53 2.744 1144089 77765 802885 378449 01 63.695 3.34 12964867 Not done 797253 0 1 66.95 3.344 1294087 79000 91.420 797253 0 1 65.42 4.30 12534987 12820065 756540 1381905 3 65.42 4.30 12534987 79029778 840431 575991 1 69.09 2.744 8427442 7696344 495373 4	Examined Positive	^o sitive		Positive for	smears with Plasmodium	incidence (No. of confirmed	Targeted po (% cove	pulation rage)	Quantity us	ed in kg	cases
57.86 3.61 14658872 Not done 877904 0 $(79,67)$ $(79,67)$ $(79,67)$ $(79,67)$ $(79,67)$ 0 $(79,53)$ $(79,53)$ $(79,50)$ $(61,89)$ 339453 339453 61.37 3.15 14592590 6967822 937238 339453 61.97 3.48 15645797 Not done 917766 0 1 61.97 3.48 155645797 Not done 917766 0 1 61.33 3.21 14908712 5838094 823537 292956 62.30 3.21 14008712 5838094 823537 292956 62.30 3.21 14008712 5838094 823537 292956 62.30 3.21 14144089 7071625 802885 378449 63.53 2.74 11414089 7071625 802885 378449 71.21 2.02 11842156 Not done 797253 0 1 60.95 3.34 12264867 Not done 797253 0 1 66.95 3.34 12264867 Not done 797253 0 1 69.09 3.19 1233487 12264867 Not done 797253 0 1 69.09 3.19 1233487 12264867 Not done 797253 0 1 69.09 3.19 1233487 12264867 Not done 797253 0 1 69.09 3.19 13365385 <th>u ()</th> <th>barasite (%)</th> <th>-</th> <th>falciparum (%)</th> <th>falciparum</th> <th>cases/1,000 population</th> <th>Ist spray</th> <th>2nd spray</th> <th>lst</th> <th>2nd</th> <th></th>	u ()	barasite (%)	-	falciparum (%)	falciparum	cases/1,000 population	Ist spray	2nd spray	lst	2nd	
63.38 4.91 15436286 6031876 1081477 363830 1 61.37 3.15 (81.86) (76.90) (76.90) 61.872 339453 339453 61.97 3.15 14592590 697822 937238 339453 339453 61.97 3.48 15645797 Not done 917766 0 1 61.97 3.21 14008712 5838094 823537 292956 62.30 3.21 14008712 5838094 823537 292956 62.30 3.21 140408712 5838094 823537 292956 63.53 2.744 14144089 7071625 802885 378449 77121 2.02 11842156 Not done 74801 0 7121 2.02 11842156 Not done 797253 0 1 66.95 3.34 122964867 Not done 797253 0 1 66.96 3.19 12363385 10929778 840431 575991 1 69.09 3.19 13365385 10929778 840431 575991 1 69.30 2.74 8427442 7696344 495373 428912 1 69.30 2.74 8407742 7696344 495373 428912	2441084 94645 (9.34) (3.87)	94645 (3.87)		54769 (2.24)	57.86	3.61	14658872 (79.67)	Not done	877904	0	34
61.37 3.15 14592590 6967822 937238 339453 61.97 3.48 (79.30) (61.89) 017766 0 1 61.97 3.48 15645797 Not done 917766 0 0 62.30 3.21 14008712 5838094 823537 292956 63.53 2.74 14144089 7071625 802885 378449 771.21 2.02 11842156 Not done 74801 0 71.21 2.02 11842156 Not done 74801 0 66.95 3.34 12964867 Not done 797253 0 66.95 3.34 12964867 Not done 797253 0 1 69.09 3.19 12365385 10929778 840431 575991 1 69.09 2.74 8427442 7696344 495373 428912 175091 1 69.30 2.74 840742 7696344 495373 428912 1	2872859 131048 (10.78) (4.56)	31048 (4.56)		83064 (2.89)	63.38	4.91	15436286 (81.86)	6031876 (76.90)	1081477	363830	111
61.97 3.48 15645797 (77.02) Not done 917766 01 62.30 3.21 (77.02) 5838094 823537 292956 63.53 2.74 141089 7071625 802885 378449 63.53 2.74 14144089 7071625 802885 378449 71.21 2.02 11842156 Not done 74801 0 66.95 3.34 12964867 Not done 797253 0 66.95 3.34 12964867 Not done 797253 0 66.96 3.19 123534987 12820065 756540 1381905 3 69.09 3.19 12534987 12820065 756540 1381905 3 69.09 3.19 (74.00) (91.42) (75.21) 840431 575991 1 69.30 2.74 8427442 7696344 495373 428912 756931 1	2215375 84915 (8.23) (3.83)	84915 (3.83)		52116 (2.35)	61.37	3.15	14592590 (79.30)	6967822 (61.89)	937238	339453	43
62.30 3.21 14008712 5838094 823537 292956 63.53 2.74 14144089 7071625 802885 378449 63.53 2.74 14144089 7071625 802885 378449 71.21 2.02 111842156 Not done 74801 0 66.95 3.34 12264867 Not done 797253 0 1 66.95 3.34 122964867 Not done 797253 0 1 66.95 3.34 12364867 Not done 797253 0 1 66.96 3.34 12364867 Not done 797253 0 1 66.99 3.34 12364867 Not done 797253 0 1 66.99 3.34 12364867 Not done 797253 0 1 66.99 3.19 12820065 756540 1381905 3 69.09 3.19 13365385 10929778 840431 575991 1 69.30 2.74 8427442 7696344 495373 428912 179.00 (79.00) (78.00) (78.00) (78.00) 495373 428912	2432620 95142 (8.90) (3.91)	95142 (3.91)		58951 (2.48)	61.97	3.48	15645797 (77.02)	Not done	917766	0	122
	2325105 89601 (8.32) (3.85)	89601 (3.85)		55825 (2.40)	62.30	3.21	14008712 (70.80)	5838094 (70.63)	823537	292956	72
71.21 2.02 11842156 Not done 74801 0 66.95 3.34 12964867 Not done 797253 0 1 66.95 3.34 12964867 Not done 797253 0 1 65.42 4.30 12534987 12820065 756540 1381905 3 65.42 4.30 12534987 12820065 756540 1381905 3 69.09 3.19 13365385 10929778 840431 575991 1 69.30 2.74 8427442 7696344 495373 428912 69.301	2133820 76570 (7.66) (3.85)	76570 (3.85)		48647 (2.27)	63.53	2.74	14144089 (77.45)	7071625 (90.00)	802885	378449	53
66.95 3.34 12964867 Not done 797253 0 1 65.42 4.30 12834987 12820065 756540 1381905 3 65.42 4.30 12534987 12820065 756540 1381905 3 69.09 3.19 13355385 10929778 840431 575991 1 69.09 3.19 13365385 10929778 840431 575991 1 69.09 3.19 13365345 10929778 840431 575991 1 69.30 2.74 8427442 7696344 495373 428912 69.30 2.74 8427442 7696344 495373 428912	1853560 58134 (6.45) (3.13)	58134 (3.13)		41400 (2.23)	71.21	2.02	11842156 (81.00)	Not done	748801	0	52
65.42 4.30 12534987 12820065 756540 1381905 3 69.09 3.19 13365385 10929778 840431 575991 1 69.30 2.74 8427442 7696344 495373 428912 69.30 2.74 8427442 7696344 495373 428912	2050261 67885 (7.06) (3.31)	67885 (3.31)		45453 (2.21)	66.95	3.34	12964867 (78.00)	Not done	797253	0	113
69.09 3.19 13365385 10929778 840431 575991 1 69.30 2.74 8427442 7696344 495373 428912 1	2743092 126178 (9.35) (4.59)	26178 (4.59)		82546 (3.00)	65.42	4.30	12534987 (74.00)	12820065 (91.42)	756540	1381905	304
69.30 2.74 8427442 7696344 495373 428912 (79.00) (78.00) (78.00) (78.00) (78.00) (78.00)	2399836 94853 (8.09) (3.12)	94853 (3.12)		65542 (2.73)	60.09	3.19	13365385 (81.72)	10929778 (75.21)	840431	575991	152
	2687756 83939 (8.62) (3.12)	83939 (3.12)		58124 (2.20)	69.30	2.74	8427442 (79.00)	7696344 (78.00)	495373	428912	86

Age-group (yrs)	0	-4	5	-9	9	-14		≥15	Total	cases		
Year	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female		
2007	13	08	07	12	11	12	55	34	86	66		
2008**	11	10	06	03	04	06	32	14	53	33		
2009**	09	04	04	04	04	04	22	08	39	20		
Total**	33	22	17	19	19	22	109	56	178	119		

Table 2 Distribution of malaria-attributable death cases by age and gender during 2007–2009 in Assam, northeast India*

*Source, State Health Directorate of Assam

**Number of death cases were significantly higher in males (P = <0.05) of which majority were in >15 age group (P = <0.001)

for the years (1991–2008) revealed that every 3–4 years there was unusual rise in *P. falciparum* cases and malaria deaths mostly along bordering population groups (Fig. 2). For the districts investigated for disease outbreaks during 1988–2006, it was observed that in the affected population, *A. minimus* was the predominant vector species incriminated by dissection and demonstration of the sporozoites (Table 3). In 2006, 304 confirmed deaths were recorded in Assam, the highest in last 15 years. All border districts were adversely

affected, of which Lakhimpur (sharing an inter-state border with Arunachal Pradesh) reported 82 deaths, highest in the state. Deaths were reported from all age groups (excluding <1 year) of both sexes, most of which were attributed to late reporting. Among the deceased, majority (44%) died the same day of hospital admission, 39% died within 2 days, 14% within 3 days, and the remaining in \geq 3 days of hospital care (Source, Chief Medical and Health Officer, Civil Hospital, Lakhimpur). As per hospital records, during outbreak period



Fig. 1 A sketch map of Assam showing geographical proximity to Bhutan, Bangaldesh and Myanmar




Fig. 2 Malaria-attributable morbidity due to *Plasmodium falciparum* cases and deaths in Assam during 1991–2008 (Source, State Health Directorate of Assam)

(April–June 2006), of total admissions in the hospital, 85% were due to malaria with severe complications that included hepatic jaundice, renal failure and cerebral involvement in decreasing order. The actual death toll is always high as this does not include fever-related deaths lacking blood-smear examination report.

Stratification based on API for the period 2004–2008, revealed that the increase in districts reporting API >10 was at the expense of low endemic districts (API <1) due to sudden spurt of *P. falciparum* associated with death cases, whereas districts reporting moderate endemicity were stable

with little variation (Fig. 3). The common denominator was that the affected population groups were located along borders where healthcare access was poor and distant. These villages were inaccessible and communities were poorly informed of disease prevention and control. Disease surveillance was scarce resulting in build up of gametocyte reservoir and vector density amounting to increased risk of malaria. In such complex emergencies, it is advisable to strengthen interventions by focal DDT spray operations, impregnation of community-owned mosquito nets, early diagnosis and treatment.

Table 3 Relative abundance of Anopheles minimus,	s, sporozoite infectivity, mosquito biting and entomological inoculation rate	es
(EIRs), and prevalence of malaria in districts of Assam r	reporting focal disease outbreaks, northeast (India)*	

District	District Location		Daytime resting	Mean biting/ rate/person/	No. mosquitoes	EIR (MBR × sporozoite	% positivity in clinical cases of malaria	
			collections per person hour	night (MBR)	dissected (sporozoite rate)	rate) per person/night	Plasmodium falciparum	P. vivax
Kamrup	Sonapur	Jun–Oct 1988	07.00	14.00	332 (0.033)	0.46	17.0	11.0
Sonitpur	Rangapara	Jul-Sep 1992	02.00	13.00	142 (0.042)	0.55	42.8	10.2
Darrang	Tangla	Aug-Sep 1992	11.00	20.00	382 (0.031)	0.62	48.0	8.1
Golaghat	Bokakhat	May–Jul 1994	05.35	12.25	303 (0.010)	0.12	6.2	22.8
Goalpara	Agia	Apr-May 1995	0.95	18.75	105 (0.029)	0.54	34.5	13.4
Morigaon	Nellie	Jul–Aug 1999	02.87	23.00	130 (0.031)	0.71	39.4	4.1
Lakhimpur	Boginadi	Apr–Jun 2006	07.00	34.00	No data	_	18.9	10.6

*Source, Dev et al. 2004

Drug policy and changing transmission profiles

Ever since inception of control program in 1950s, chloroquine has been the drug of choice for treatment of both P. falciparum and P. vivax cases. It is in 1973 that resistance to chloroquine for treatment of P. falciparum was first documented in Karbi Anglong district of Assam (Sehgal et al. 1973). Since then drug-resistant foci have multiplied and spread widely in most parts of India resulting in steady increase in proportions of P. falciparum from 13% in 1978 to presently 50% of those reported in India (Sharma 1996, 2000; Mohapatra et al. 2003). Development and spread of drug-resistance is a major challenge and is responsible for increased morbidity and mortality in northeastern states. Periodic assessment of therapeutic efficacy in malaria endemic districts led to change of drug policy for treatment of drug-resistant malaria (Table 4). Consequent to research inputs, it was in 2004 that there was switch from chloroquine (CQ) to sulfadoxine-pyrimethamine (SP) as first-line of therapy in select districts with documented chloroquine resistance (Source, State Health Directorate). In 1990s, the development of artemisinin derivative, i.e. alpha-beta arteether and its clinical assessment as monotherapy raised new hopes to control drug-resistant malaria. It was evaluated to be fast acting schizontocidal drug that was convenient for treatment of severe and complicated P. falciparum cases (Asthana et al. 2001). Beginning 2007, NVBDCP adopted artemisinin-based therapy by combining SP (that was already in use) with artesunate for treatment of every confirmed case of *P. falciparum* in high-risk districts that have been declared chloroquine-resistant. Therapeutic assessment

of this combination in different malaria endemic pockets resulted in rapid parasite clearance, and was concluded to be safe and effective for treatment of *P. falciparum* malaria (Dev et al. 2009).

Implementation of the revised drug policy resulted in drastic reduction in cases as evidenced in the Sonapur Primary Health Centre (Dimoria block) of Kamrup district of Assam (Table 5). Data from 2004-2008 revealed that SP therapy in 2004 resulted in appreciable reduction in P. falciparum cases in 2005 but that was not sustainable resulting in 2-fold rise in the following year. However, introduction of artesunate + sulfadoxine-pyrimethamine (AS + SP) artemisinin-based combination therapy (ACT) in 2007 amounted to notable reduction in case incidences over 2 year study period. The transmission profile of malaria had changed noticeably indicating declining trends of P. falciparum (Fig. 4). Similarly, other recommended ACTs that included artesunate + mefloquine (AS + MQ), artemether + lumefantrine (AL) and dihydroartemisinin + piperaquine (DHA + PQP) that were subject to assessment in northeast reported cure rate >95%, and were concluded to be safe and effective as alternate drugs (Neena Valecha, personal communication). Newer ACTs such as artesunate + pyronaridine (AS + PRN), and potent molecules (acridones) offer a powerful approach to address the gaps and weaknesses in the existing armamentarium of the combination therapies available at present (Ramharter et al. 2008; Kelly et al. 2009). We strongly advocate rolling out ACT for every single case of P. falciparum to avert impending disease outbreaks, and help contain spread of drug-resistant malaria. Based on research inputs, ACTs have been adopted by the NVBDCP for all districts of Assam beginning 2009.




Fig. 3 Malaria stratification based on parasite incidence per thousand population/year for districts of Assam during 2004–2008

Antimalarial treatment	District (state)	Study period		No. and (%) of subject	ts parasitem	ic on follow	up day of	
			Day 0	Day 2	Day 3	Day 7	Day 14	Day 21	Day 28
CQ ¹	Kamrup and Nalbari (Assam)	2000–02	144 (100)	23 (15.9)	17 (11.8)	5 (3.5)	11 (7.6)	9 (6.3)	3 (2.1)
CQ/SP ²	Kamrup and Nalbari (Assam)	2000–02	34 (100)	4 (11.8)	2 (5.9)	1 (2.9)	1 (2.9)	0 (0)	0 (0)
SP ³	Kamrup (Assam)	2004	54 (100)	28 (50.9)	4 (7.3)	0 (0)	1 (1.8)	4 (7.3)	4 (7.3)
Alpha/beta arteether	Kamrup and Darrang (Assam)	1995–96	41 (100)	6 (14.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Kamrup and Darrang (Assam)	2005	60 (100)	50 (83)	23 (38)	3 (5)	0 (0)	0 (0)	3 (5)
$AS + SP^4$	Darrang (Assam)	2005	51 (100)	No data	0 (0)	0 (0)	0 (0)	0 (0)	3 (5.9)
	Nalbari (Assam)	2006	53 (100)	No data	1 (1.9)	0 (0)	0 (0)	4 (7.5)	2 (3.8)
	West Garo Hills (Meghalaya)	2007	54 (100)	No data	0 (0)	0 (0)	1 (1.8)	2 (3.7)	0 (0)
AL^5	Kamrup (Assam)	2007	53 (100)	10 (18.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Table 4 Therapeutic efficacy of antimalarials for treatment of *Plasmodium falciparum* malaria in northeast India

 ^{1}CQ = chloroquine, $^{2}CQ/SP$ = sequential therapy with sulfadoxine-pyrimethamine for chloroquine resistant cases, ^{3}SP = sulfadoxine-pyrimethamine $^{4}AS + SP$ = artesunate + sulfadoxine-pyrimethamine, ^{5}AL = artemether + lumefantrine

Challenges and opportunities

There are many operational constraints specific to northeast India that amount to intolerable disease burden due to malaria. Amongst shortfalls that permit persistent transmission of malaria is the manpower attrition at various levels of operation (Source, State Health Directorate). There are existing vacancies for district level functionaries amounting to poor/delayed reporting and lack of much needed supervision (Prasad 2009). Disease surveillance at present can be best described as fragmentary inclusive of misdiagnosis and poor record keeping which should be robust for timely institution of intervention measures. True incidence of malaria is estimated to be manifold due to much larger private sector for which there is no existing mechanism for data collation. There are many more cases which had the least opportunity for blood-smear examination and treatment due to geographical remoteness and inaccessibility. Worst is the large asymptomatic reservoir in the endemic communities estimated to be

in the range of 8-33% that are poorly addressed (Dev et al. 2006b). The adherence to national drug policy for treatment of cases should be enforced for government and private sector alike with increased regulation. There is need to implement a comprehensive and innovative approach for training of NGOs, private vendors, private clinics for accredited services to increase the strength and reach of the government program. Health infrastructure in the periphery remains inadequate for treatment of severe and complicated cases of malaria. Community participation for enhanced compliance for indoor residual spray operations and seeking treatment should be the guiding principle. The entomological component, the crucial epidemiological determinant for monitoring vector density and supervision of control intervention, is non-existent. A culture of performance, accountability and transparency should be established. Northeast shares lengthy borders with neighboring countries of Bhutan, Myanmar and Bangladesh that are equally malaria endemic. These borders are porous with high levels of human traffic which demands well

Year	Population	No. blood-smears examined (ABER)**	Positive for malaria parasite (%)	Positive for Plasmodium falciparum	% of positive blood-smears with Plasmodium falciparum	Annual parasite incidence (No. of confirmed cases/1,000 population)
2004*	146859	25420 (17.3)	2173 (8.54)	2006	92.31	14.79
2005	153460	22121 (14.4)	1313 (5.93)	960	73.11	8.55
2006	155721	35582 (22.8)	2551 (7.16)	1815	71.14	16.38
2007*	166491	29307 (17.6)	2152 (7.34)	1145	53	12.90
2008	166579	33925 (20.4)	584 (1.72)	279	48	3.50

Table 5 Changing transmission profiles of malaria in the Sonapur Primary Health Centre (Dimoria block) of Kamrup district of Assam, northeast India

*Sulfadoxine-pyrimethamine (SP) and artesunate + sulfadoxine-pyrimethamine (AS + SP) were implemented in 2004 and 2007 respectively for treatment of *Plasmodium falciparum* cases

**ABER denotes annual blood-smear examination rate (% population checked for malaria parasite)

supervised coordinated spray operations, and screening and treatment at entry points. Population migration across borders is one imminent threat that continues to thwart the control efforts. Unauthorized colonies have come up in erstwhile forest reserve areas where control measures are not instituted resulting in fulminating disease outbreaks and unattended parasite reservoir. Ethnic conflicts in some areas continue to plague the program resulting in uninterrupted malaria transmission. The surge of counterfeit drugs in southeast Asia (Dondorp et al. 2004; Newton et al. 2008), high refusal rates to indoor residual spraying (Prasad 2009), the slackness of workforce and treatment seeking behavior and compliance are some major challenges that need to be addressed (Dev et al. 2006b).

Enhanced allocation of resources under Global Fund against Aids, Tuberculosis and Malaria (GFATM), National




Fig. 4 Declining trends of malaria transmission in the Sonapur Primary Health Centre (Dimoria block) of Kamrup district of Assam consequent to change in drug treatment policy from chloroquine to sulfadoxine-pyrimethamine in 2004, and to ACT (artesunate + sulfadoxine-pyrimethamine) in 2007 (representative year 1999 when chloroquine was in force for treatment of *Plasmodium falciparum*) Pv = *Plasmodium vivax*, Pf = *P. falciparum*, SFR = % smear positive for *P. falciparum*, SVR = % smear positive for *P. vivax*.

Rural Health Mission (NRHM) and donors alike offer the opportunity for strengthening the healthcare services in the resource-poor settings to meet the malaria challenge. The strengthening of human resource and provision of logistic requirements on account of antimalarials (ACTs), diagnostics (RDKs) and preventive measures (ITNs/ LLINs) have resulted in substantial reduction in malaria transmission formerly intractable (Dev et al. 2008; Dev 2009). The challenge now is to ensure the sustained supply of these commodities and scale-up the interventions in reaching the population groups those are most in need. Public private partnership should be sought to meet the demand and supply at affordable prices. Political commitment for the continued support to the control program is of paramount importance failing which the gains of the preceding years may be lost. There is opportunity for coordinated action between agencies viz. defense, industry, public and private sector alike to keep malaria at bay helping restore confidence in the affected communities and boosting economic development.

Looking forward: Malaria map is shrinking so much so that as many 39 countries are contemplating malaria elimination (Greenwood 2008; Feachem and the Malaria Elimination Group 2009). Given the malaria endemicity in the northeast, concerted efforts should be made to achieve low levels of transmission prioritizing high-risk areas. We strongly advocate judicious mix of technologies that are feasible, sustainable and environment friendly based on understanding of local disease epidemiology (Beier et al. 2008). What is tantamount to economic development is the strong health delivery system to reach the outreach population groups (Whitty et al. 2008; Mendis et al. 2009). Research component should be strengthened for providing inputs to the control program updating with the new technologies for effective control. The political will for increased allocation of resources in the northeast will yield rich dividend in reducing the levels of transmission and building equitable healthcare services.

Acknowledgements We wish to thank Drs. P. K. Phukan, K. Barman and K. Khound, State Health Directorate of Assam for data access and discussions on the subject. The technical expertise of S. Phookan and project staffs is gratefully acknowledged.

References

Asthana OP, Srivastava JS, Kamboj VP, Valecha N, Sharma VP, Gupta S, Pande TK, Viswanathan KA, Mohapatra KM, Nayak NC, Mahapatra PK, Mahanta J, Srivastava VK, Dev V, Singh N, Shukla MM, Balsara AB, Mishra SK, Satpathy SK, Mohanty S, Dash B (2001) A multicentric study with Arteether in patients of uncomplicated falciparum malaria. *J Assoc Physicians India*, (JAPI) 49:692–696

- Beier JC, Keating J, Githure JI, Macdonald MB, Impoinvil DE, Novak RJ (2008) Integrated vector management for malaria control. *Malar J*, 7(Suppl 1):S4 doi:10.1186/1475–2875–7– S1–S4
- Dev V (2009) Integrated disease vector control of malaria: a success story based in Assam, northeastern India. *ICMR Bulletin*, 39:21–28
- Dev V, Bhattacharyya PC, Talukdar R (2003) Transmission of malaria and its control in the Northeastern Region of India. *J Assoc Physicians India*, (JAPI) 51:1073–1076
- Dev V, Biswas S, Joshi H, Prajapati SK, Valecha N, Dash AP (2009) Safety and efficacy of artesunate+sulfadoxine–pyrimethamine in the treatment of *Plasmodium falciparum* malaria in northeast India. *Parassitologia*, (in press)
- Dev V, Doley GC, Dash AP (2008) Rolling back malaria is possible. *Indian J Med Res*, 128:82–83
- Dev V, Dash AP, Khound K (2006a) High-risk areas of malaria and prioritizing interventions in Assam. *Curr Sci*, 90:32–36
- Dev V, Phookan S, Sharma VP, Anand SP (2004) Physiographic and entomologic risk factors of malaria in Assam, India. *Am J Trop Med Hyg*, 71:451–456
- Dev V, Phookan S, Sharma VP, Dash AP, Anand SP (2006b) Malaria parasite burden and treatment seeking behavior in ethnic communities of Assam, Northeastern India. *J Infection*, 52:131–139
- Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S, Petit A, Lynam AJ, Johnson A, Hien TT, McGready R, Farrar JJ, Looareesuwan S, Day NP, Green MD, White NJ (2004) Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational crosssectional survey on the prevalence of fake antimalarials. *Trop Med Int Health*, 9:1241–1246
- Feachem RGA and the Malaria Elimination Group (2009) Shrinking the Malaria Map: A Guide on malaria Elimination for Policy makers. San Francisco: The Global Health Group, Global Health Sciences, University of California, San Francisco, pp. 66
- Greenwood BM (2008) Control to elimination: implications for malaria research. *Trends Parasitol*, 24:449–454
- Kelly JX, Smilkstein MJ, Brun R, Wittlin S, Cooper RA, Lane KD, Janowsky A, Johnson RA, Dodean RA, Winter R, Hinrichs DJ, Riscoe MK (2009) Discovery of dual function acridones as a new antimalarial chemotype. *Nature*, 459:270–273
- Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH (2009) From malaria control to eradication: The WHO perspective. *Trop Med Int Hlth*, 14:802–809
- Mohapatra PK, Namchoom NS, Prakash A, Bhattacharya DR, Goswami BK, Mahanta J (2003) Therapeutic efficacy of anti-malarials in *Plasmodium falciparum* malaria in an Indo-Myanmar border area of Arunachal Pradesh. *Indian J Med Res*, 118:71–76

- Newton PN, Fernández FM, Plançon A, Mildenhall DC, Green MD, Ziyong L, Christophel EM, Phanouvong S, Howells S, McIntosh E, Laurin P, Blum N, Hampton CY, Faure K, Nyadong L, Soong CW, Santoso B, Zhiguang W, Newton J, Palmer K (2008) A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. *PLoS Med*, 5:e32
- Prakash A, Bhattacharyya DR, Mohapatra PK, Mahanta J (1997) Breeding and day resting habitats of *Anopheles dirus* (Diptera: Culicidae) in Assam. *Southeast Asian J Trop Med Pub Hlth*, 28:610–614
- Prakash A, Bhattacharyya DR, Mohapatra PK, Mahanta J (2001) Estimation of vectorial capacity of *Anopheles dirus* (Diptera:Culicidae) in a forest fringed village of Assam (India). *Vector Borne Zoonotic Dis*, 1:231–237
- Prakash A, Mohapatra PK, Bhattacharyya DR, Sharma CK, Goswami BK, Hazarika NC, Mahanta J (2000) Epidemiology of malaria outbreak (April/May 1999) in Titabar primary health centre, district Jorhat (Assam) *Indian J Med Res*, 111:121–126

- Prasad H (2009) Evaluation of malaria control program in three selected districts of Assam. J Vector Borne Dis, (in press)
- Ramharter M, Kurth F, Schreier C, Nemeth J, Glasenapp V, Belard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordmuller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner P (2008) Fixed–dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infec Dis, 198:911–919
- Sehgal PN, Sharma MID, Sharma SL, Gogoi S (1973) Resistance to chloroquine in falciparum malaria in Assam State, India. *J Comm Dis*, 5:175–180
- Sharma VP (1996) Re-emergence of malaria in India. Indian J Med Res, 103:26–45
- Sharma VP (2000) Status of drug resistance in malaria in India. In: Multi-drug resistance in emerging and re-emerging diseases. Mahajan RC (Ed.) Indian National Science Academy, Delhi, Narosa Publications, pp. 191–202
- Whitty CJM, Chandler C, Ansah E, Leslie T, Staedke SG (2008) Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. *Malar J* 7(Suppl 1):S7 doi:10.1186/1475–2875–7–S1–S7